Product Description
Merck KGaA is developing ngm-313, a subcutaneous FGFR1 Agonist for Obese Participants With Insulin Resistance and Increased Liver fat. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03298464)
Mechanisms of Action: FGFR1 Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Canada, Chile, China, Colombia, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Malaysia, Mexico, New Zealand, Peru, Puerto Rico, Russia, South Africa, South Korea, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2051200083 |
jRCT2051200083 | P2 |
Active, not recruiting |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
2024-09-30 |
63% |
||
CTR20210074 |
CTR20210074 | P2 |
Completed |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
2023-04-13 |
2025-04-29 |
||
2019-003048-63 |
2019-003048-63 | P2 |
Completed |
Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic |
2023-04-13 |
63% |
2025-07-06 |
Treatments |